凯普生物：公司及子公司获多项发明专利授权

Group 1 - The core viewpoint of the articles is that Capbio (300639) has obtained five invention patents in January 2026, which enhance the company's intellectual property strength and product competitiveness in the fields of bioengineering, microdroplet generation, cell sorting, and nucleic acid testing [1][2] Group 2 - The patents include methods and systems for hybrid analysis, microdroplet generation, live cell sorting, sample preservation, and sample division, which have been authorized in China and Brazil [1] - The patented technologies address industry pain points, such as improving detection accuracy, ensuring consistent droplet volume, increasing sorting accuracy, and effectively preserving viral nucleic acids at room temperature for up to 16 days [1] Group 3 - Capbio aims to become a leading enterprise in nucleic acid molecular diagnostics and is advancing its "Nucleic Acid 99" strategy, which aligns with its development strategy and enhances its core competitiveness [2]